Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

about

The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.

P2860

Q47665634-B8346427-CA25-4F0D-9D67-22D9EBC04DC8

P2860

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

Item

http://www.wikidata.org/entity/Q35582654

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@ast

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@en

type

Item

label

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@ast

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@en

prefLabel

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@ast

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@en

P1476

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

@en

P2093

Allison Gaudy

http://www.w3.org/2001/XMLSchema#string

Elena Kurenova

http://www.w3.org/2001/XMLSchema#string

Gerald Fetterly

http://www.w3.org/2001/XMLSchema#string

John Wilton

http://www.w3.org/2001/XMLSchema#string

Laura Pitzonka

http://www.w3.org/2001/XMLSchema#string

Leslie Curtin

http://www.w3.org/2001/XMLSchema#string

Sandra Sexton

http://www.w3.org/2001/XMLSchema#string

William Cance

http://www.w3.org/2001/XMLSchema#string

P2860

Antihistamine agents; halogenated N,N-dimethyl-N-benzyl-N-(2-pyridyl)-ethylenediamines

Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view.

Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis.

Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.

The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.

P2888

s13318-014-0233-6

P304

55-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13318-014-0233-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25377246

http://www.w3.org/2001/XMLSchema#string

P932

4424193

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

about

P2860

P2860

Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932